Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SLV354 · 1 trial · 1 indication
5-HT6 receptor occupancy and the relationship between SLV354 plasma concentrations and receptor occupancy
| Arm | Type | Description |
|---|---|---|
| Group 1 (healthy), Group 2 (schizophrenia) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SLV354 | DRUG | One dose of ABT-354 |
Inclusion Criteria 1. Male, age between 18 and 55 years, inclusive. 2. Body Mass Index 18 to 30 (healthy) and 18 to 38 (schizophrenia). 3. A condition of general good physical health. 4. Schizophrenia subjects must have a diagnosis of schizophrenia based on Diagnostic and Statistical Manual of Ment...
SLV354 is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and tolerability in early-stage trials.
SLV354 is being developed by Abbott Laboratories, a company publicly traded under the ticker symbol ABT. The drug is an investigational small molecule intended for the treatment of schizophrenia and is currently in Phase 1 clinical development.
SLV354 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing for schizophrenia.
SLV354 has been studied in one completed Phase 1 clinical trial, identified as NCT01545310. This was a positron emission tomography study conducted in the United States that enrolled 18 male participants, including healthy volunteers and subjects with schizophrenia.
SLV354 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information. It is being developed by Abbott Laboratories for the treatment of schizophrenia.